Axitinib(Inlyta)

Axitinib is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) following failure of prior systemic therapy.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Axitinib Drug News

FDA Approves Bavencio (Avelumab) in Combination with Inlyta (Axitinib) for Patients with Advanced Re

Darmstadt, Germany & New York, NY, USA – May 14, 2019 – Merck KGaA, Darmstadt, Germany (operating its biopharma business in the U.S. and Canada as···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 70
Pembrolizumab Combined with Axitinib Yields Durable Clinical Benefits in Advanced Renal Cell Carcino

Friday, August 8, 2025 — A study published online in Nature Medicine on August 6 demonstrated that the treatment regimen of pembrolizumab combined wit···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 71

Bigbear Pharmaceutical